Articlebronze2022

Covid‐19 vaccination in autoimmune rheumatic diseases: A multi‐center survey from southern India

Kavitha Mohanasundaram · Sham Santhanam · Raja Natarajan · Hema Murugesan · Thilagavathy Nambi · Balaji Chilikuri +1 more

27 citations0/0 files storedInternational Journal of Rheumatic Diseases

No readable copy stored yet — this record is metadata only.

No open-access location is known for this record yet.

Literature note Cite in a project Citation map

Vaccine Coverage and Hesitancy Rheumatoid Arthritis Research and Therapies SARS-CoV-2 and COVID-19 Research

Abstract

AIM: This survey was conducted to evaluate COVID-19 vaccination status in patients with autoimmune rheumatic diseases (AIRDs). Our objectives were to study vaccine hesitancy, adverse effects, breakthrough infections and flare of underlying disease in this population subgroup. METHODS: This was a multi-center, cross-sectional, interview-based survey done at 6 tertiary care centers across Tamil Nadu, in the southern part of India from September 15, 2021 to October 14, 2021. The survey questionnaire was filled up by AIRD patients attending their clinics. The survey questionnaire comprised a set of 14 questions, distributed between patient characteristics, vaccines taken, their characteristics and COVID-19 infection. RESULTS: There were 2092 participants, with a mean age of 47.5 ± 13.17 years. Among them, 1293 (61.81%) were vaccinated, of which 837 (64.73%) were fully vaccinated. Two-thirds of our subjects were vaccinated with ChAdOx1 nCov-19 (COVISHIELD) (77.64%) and 21.57% with BBV 152 (COVAXIN). Age, gender, education and comorbidities had no association with vaccine hesitancy. The commonest (421; 52.69%) reason for vaccine hesitancy was fear of side effects. The incidence (n = 72) of breakthrough infections was similar in both the vaccine groups, of which 58 (80.55%) were partially vaccinated and 14 (19.44%) were fully vaccinated. Thirty-two patients had a flare of pre-existing rheumatic disease. CONCLUSION: ChAdOx1 nCov-19 and BBV 152 were found to be safe in patients with rheumatic diseases. Fear of side effects was the major cause of vaccine hesitancy. All adverse effects were minor and self-limiting. Breakthrough infections and disease flares occurred only in a small subset of our cohort.

Paper brief

Loading…

Cite this work

Citation unavailable for this work.

BibTeX RIS CSL-JSON

No public copy is stored for this record, so only the metadata is cited.

Citations in this library

Citation map →

Stored only when both papers are in the corpus — 27 citations exist upstream.

References

2021COVID-19 Vaccine Hesitancy in the United States: A Systematic Review 2021Strategy for COVID-19 vaccination in India: the country with the second highest population and number of cases 2021Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey 2021Vaccination against COVID-19: Expectations and concerns of patients with autoimmune and rheumatic diseases 2021COVID-19 vaccine hesitancy in patients with systemic autoimmune rheumatic disease: an interview-based survey 2021COVID-19 vaccine safety and nocebo-prone associated hesitancy in patients with systemic rheumatic diseases: a cross-sectional study 2022COVID‐19 vaccination in patients with rheumatic diseases: Vaccination rates, patient perspectives, and side effects

Explore the map →

Papers that cite the same references — the relational fallback while embeddings are still backfilling.

Imported from OpenAlex (CC0) — nothing here is generated.